Dr. Paul Camarata, a neurosurgeon and investigator for the MISTIE trial, was interviewed today about the successful treatment of a patient at the University of Kansas Medical Center. MIS stands for minimally-invasive surgery and is the technique used to place a catheter into the patient's intracerebral hematoma. (ICH, also called intracerebral hemorrhage, is a type of stroke caused by bleeding in the brain). A drug called tissue plasminogen activator (tPA) is then administered into this catheter for 1 to 3 days to breakup the blood clot (by enhancing a natural process called thrombolysis) so it can be drained out of the catheter.
During the interview, Dr. Camarata mentions the MISTIE Phase II trial that recently completed enrollment (see Dr. Hanley's presentation on the full study results) and talks about the forthcoming MISTIE Phase III trial.
Original report by Meryl Lin McKean of Fox-4 TV Kansas City